

Cited Literature

1. Esteller, M. Relevance of DNA methylation in the management of cancer. *The Lancet Oncology* 4, 351-358 (2003).
2. Toyooka, S., et al. Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. *Cancer Research* 62, 3382-3386 (2002).
3. Zou, H.Z., et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. *Clin Cancer Res* 8, 188-191 (2002).
4. Ebert, M.P., et al. Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers. *Neoplasia (New York, N.Y)* 7, 771-778 (2005).
5. American Cancer Society. *Colorectal Cancer Facts & Figures Special Edition 2005*. Atlanta: American Cancer Society, 2005.
6. Davies, R.J., Miller, R. & Coleman, N. Colorectal cancer screening: prospects for molecular stool analysis. *Nature reviews* 5, 199-209 (2005).
7. Walsh, J.M. & Terdiman, J.P. Colorectal cancer screening: scientific review. *JAMA* 289, 1288-1296 (2003).
8. Cokkinides V, B.P., Siegel R, Ward EM, Thun MJ. *Cancer Prevention & Early Detection Facts & Figures 2008*. Atlanta, GA: American Cancer Society. (2007).
9. Levin, B., et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous Polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *CA: a cancer journal for clinicians* 58, 130-160 (2008).
10. Winawer, S.J. Screening sigmoidoscopy: can the road to colonoscopy be less traveled? *Annals of Internal Medicine* 139, 1034-1035 (2003).
11. Widschwendter, M. & Jones, P.A. The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Commentary re: J. Kwong et al., Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. *Clin. Cancer Res.*, 8: 131-137, 2002, and H-Z. Zou et al., Detection of aberrant p16 methylation in the serum of colorectal cancer patients. *Clin. Cancer Res.*, 8: 188-191, 2002. *Clin Cancer Res* 8, 17-21 (2002).
12. Jones, P.A. & Laird, P.W. Cancer epigenetics comes of age. *Nature Genetics* 21, 163-167 (1999).
13. Baylin, S.B., et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. *Human molecular genetics* 10, 687-692 (2001).
14. Toyota, M., et al. Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors. *Cancer Research* 60, 4044-4048 (2000).
15. Eads, C.A., et al. MethyLight: a high-throughput assay to measure DNA methylation. *Nucleic Acids Research* 28, E32 (2000).

16. Cottrell, S.E., et al. A real-time PCR assay for DNA-methylation using methylation-specific blockers. *Nucleic acids research* 32, e10 (2004).
17. Lofton-Day, C., et al. DNA methylation biomarkers for blood-based colorectal cancer screening. *Clinical Chemistry* 54, 414-423 (2008).
18. Model, F., et al. Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease. *Mol Cancer Res* 5, 153-163 (2007).
19. Surka, M.C., Tsang, C.W. & Trimble, W.S. The mammalian septin MSF localizes with microtubules and is required for completion of cytokinesis. *Molecular Biology of the Cell* 13, 3532-3545 (2002).
20. Osaka, M., Rowley, J.D. & Zeleznik-Le, N.J. MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25). *Proceedings of the National Academy of Sciences of the United States of America* 96, 6428-6433 (1999).
21. Russell, S.E., et al. Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors. *Cancer Research* 60, 4729-4734 (2000).
22. Burrows, J.F., et al. Altered expression of the septin gene, SEPT9, in ovarian neoplasia. *The Journal of Pathology* 201, 581-588 (2003).
23. Kuhlenbaumer, G., et al. Mutations in SEPT9 cause hereditary neuralgic amyotrophy. *Nature Genetics* 37, 1044-1046 (2005).
24. Lynch, H.T. & de la Chapelle, A. Hereditary colorectal cancer. *The New England Journal of Medicine* 348, 919-932 (2003).
25. Rex, D.K., Lehman, G.A., Hawes, R.H., Ulbright, T.M. & Smith, J.J. Screening colonoscopy in asymptomatic average-risk persons with negative fecal occult blood tests. *Gastroenterology* 100, 64-67 (1991).